Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea
NCT00230581 is registered in ClinicalTrials.gov with Dynogen Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea
- Lead sponsor
- Dynogen Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- August 31, 2007
- Enrollment
- 88 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.